A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).
Mezzanotte-Sharpe J, ONeill A, Mayer IA, Arteaga CL, Yang XJ, Wagner LI, Cella D, Meropol NJ, Alpaugh RK, Saphner TJ, Swaney RE, Hoelzer KL, Gradishar WJ, Abramson VG, Sundaram PK, Jilani SZ, Perez EA, Lin NU, Jahanzeb M, Wolff AC, Sledge GW, Reid SA.
Mezzanotte-Sharpe J, et al. Among authors: yang xj.
Res Sq [Preprint]. 2024 Apr 29:rs.3.rs-4295044. doi: 10.21203/rs.3.rs-4295044/v1.
Res Sq. 2024.
PMID: 38746356
Free PMC article.
Preprint.